FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns a pharmaceutical composition for treating hGH deficiency in the form of a solid oral dosage form which contains human growth hormone (hGH) and N(5-chlorsalicyloyl)-8-aminocaprylic acid (5-CNAC); a method of treating hGH deficiency which involves administering the above pharmaceutical composition into the patient.
EFFECT: group of inventions provides rapid absorption of hGH and good acceptability.
10 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2469709C2 |
| CRYSTALLINE FORMS OF DISODIUM SALT OF N-(5-CHLOROSALICILOUL-)-8-AMINOCAPRYLIC ACID | 2006 |
|
RU2507196C2 |
| PERORAL INTRODUCTION OF CALCITONIN | 2003 |
|
RU2355417C2 |
| APPLICATION OF CALCITONIN FOR TREATING RHEUMATOID ARTHRITIS | 2006 |
|
RU2453330C2 |
| 5-CNAC AS AGENT FOR ORAL DELIVERY OF PARATHYROID HORMONE FRAGMENTS | 2002 |
|
RU2322256C2 |
| CALCITONIN USED AT OSTEOARTHRITIS | 2004 |
|
RU2368390C2 |
| PHARMACEUTICAL COMPOSITIONS FOR PERORAL INTAKE OF PHARMACOLOGICAL ACTIVE SUBSTANCES | 2001 |
|
RU2287999C2 |
| ORAL ADMINISTRATION OF PARATHYROID HORMONE AND CALCITONIN | 2002 |
|
RU2300392C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HUMAN GROWTH HORMONE FOR TREATING GROWTH HORMONE DEFICIENCY | 2017 |
|
RU2732113C2 |
| TREATING DIABETES AND METABOLIC SYNDROME | 2010 |
|
RU2537181C2 |
